Payment overview · 2025
General Payments
$539.96
14 reported records · 7 companies
Healthcare provider profile · identity verified
James Wright Pilcher, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOUISVILLE, GA · NPI 1942230107
Verified facts
What the public records show
CMS Open Payments records show James Wright Pilcher, M.D. received $539.96 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $167.64 | 31.1% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $124.55 | 23.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $93.53 | 17.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $81.84 | 15.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.62 | 6.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.31 | 3.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.47 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $539.96 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $130.04 | 2 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $124.55 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $93.53 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $81.84 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $37.60 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.25 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 95 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
95 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 445 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 389 | 91 |
| Potassium Chloride | Potassium Chloride | 297 | 66 |
| Losartan Potassium | Losartan Potassium | 290 | 69 |
| Jardiance | Empagliflozin | 259 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 254 | 70 |
| Metformin Hcl | Metformin Hcl | 209 | 46 |
| Furosemide | Furosemide | 198 | 44 |
| Gabapentin | Gabapentin | 194 | 43 |
| Eliquis | Apixaban | 179 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 37 |
| Carvedilol | Carvedilol | 155 | 33 |
| Meloxicam | Meloxicam | 155 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 32 |
| Tramadol Hcl | Tramadol Hcl | 147 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 142 | 33 |
| Ezetimibe | Ezetimibe | 137 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 34 |
| Chlorthalidone | Chlorthalidone | 129 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 25 |
| Allopurinol | Allopurinol | 116 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 27 |
| Lisinopril | Lisinopril | 107 | 28 |
| Doxepin Hcl | Doxepin Hcl | 104 | 23 |
| Prednisone | Prednisone | 102 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 97 | 28 |
| Farxiga | Dapagliflozin Propanediol | 95 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 85 | 20 |
| Alprazolam | Alprazolam | 80 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 15 |
| Indapamide | Indapamide | 73 | 15 |
| Trazodone Hcl | Trazodone Hcl | 72 | 11 |
| Metformin Hcl Er | Metformin Hcl | 71 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 22 |
| Ozempic | Semaglutide | 64 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 15 |
| Donepezil Hcl | Donepezil Hcl | 54 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 13 |
| Labetalol Hcl | Labetalol Hcl | 48 | suppressed |
| Celecoxib | Celecoxib | 46 | 12 |
| Ibuprofen | Ibuprofen | 46 | 15 |
| Montelukast Sodium | Montelukast Sodium | 46 | 12 |
| Cefdinir | Cefdinir | 45 | 22 |
| Benazepril Hcl | Benazepril Hcl | 44 | suppressed |
| Glimepiride | Glimepiride | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 12 |
| Topiramate | Topiramate | 43 | suppressed |
| Pregabalin | Pregabalin | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Omeprazole | Omeprazole | 39 | 11 |
| Irbesartan | Irbesartan | 38 | suppressed |
| Simvastatin | Simvastatin | 38 | 11 |
| Sucralfate | Sucralfate | 38 | suppressed |
| Fluconazole | Fluconazole | 34 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Famotidine | Famotidine | 32 | 12 |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 27 |
| Ondansetron Odt | Ondansetron | 28 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Linzess | Linaclotide | 27 | 11 |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 14 |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 20 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 12 |
| Diazepam | Diazepam | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Dofetilide | Dofetilide | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $539.96 · 14 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, FARXIGA, Kerendia, Ozempic, QULIPTA, REXULTI, Rybelsus, Zilbrysq | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error